Postoperative treatment with the oral factor XIa inhibitor milvexian could help prevent the incidence of venous thromboembolism (VTE) in patients undergoing elective knee arthroplasty, according to results of a phase II trial presented at AHA 2021.
Indications/Uses : Adjunct to diet when response to diet & other non-pharmacological treatments (eg, exercise, wt reduction) is inadequate in adults, adolescents & childn ≥6 yr w/ primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb). Adjunct to diet & other lipid-lowering treatments (eg, LDL apheresis) or if such treatments are not appropriate in adults, adolescents & childn ≥6 yr w/ homozygous familial hypercholesterolaemia. Decrease elevated total cholesterol (total-C), LDL-cholesterol (LDL-C) & triglycerides (TG) & increase high density lipoprotein cholesterol (HDL-C) in adults w/ primary hypercholesterolemia (heterozygous familial & non-familial) or mixed dyslipidemia (Fredrickson types IIa & IIb). Decrease Apo B, non-HDL-C, VLDL-C, VLDL-TG, LDL-C/HDL-C & Apo B/Apo A-I ratios & increase Apo A-I in adults. Isolated hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Primary dysbetalipoproteinemia (Fredrickson type III hyperlipoproteinemia). Decrease total-C & LDL-C in patients w/ homozygous familial hypercholesterolaemia as adjunct to other lipid-lowering treatments or alone. Slow progression of atherosclerosis to decrease total-C & LDL-C. Decrease total-C, LDL-C & Apo B levels in childn & adolescents 6-17 yr (boys ≥ Tanner Stage II & girls who are at least 1 yr post-menarche) w/ heterozygous familial hypercholesterolaemia. Decrease risk of stroke, MI & arterial revascularization procedures in individuals w/o clinically evident CHD but w/ increased risk of CV disease.
Indications/Uses : Substitution therapy in adult patients w/ normal sinus rhythm already controlled by ivabradine & carvedilol taken concomitantly at the same dose level for symptomatic chronic stable angina pectoris in CAD patients; chronic heart failure (NYHA class II-IV) w/ systolic dysfunction.
Contents : Co-amoxiclav (amoxicillin & clavulanic acid). Per Zisuva 375 FC tab Amoxicillin 250 mg, clavulanic acid 125 mg. Per Zisuva 625 FC tab Amoxicillin 500 mg, clavulanic acid 125 mg. Per Zisuva 1G FC tab Amoxicillin 875 mg, clavulanic acid 125 mg. Per Zisuva DS powd for oral susp 5 mL Amoxicillin 125 mg, clavulanic acid 31.25 mg
Indications/Uses : Otitis media, sinusitis, infections caused by susceptible organisms involving the lower resp tract, skin & skin structure, & urinary tract w/ additional coverage of β-lactamase producing B. catarrhalis, H. influenzae, N. gonorrhoeae & S. aureus (not MRSA) in patients w/ amoxicillin resistance & those who cannot tolerate alternative treatments.
Indications/Uses : Renal tubular acidosis (RTA) w/ Ca stones; hypocitraturic Ca oxalate nephrolithiasis of any etiology; uric acid lithiasis w/ or w/o Ca stones. Prevention of stone relapse after extracorporeal shock wave lithotripsy (ESWL) or lithotomy.